MRK's growing pipeline, acquired assets and new product launches are gaining traction as it builds a diversified growth base ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so ...

Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...

Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming ...

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with ...

Moderna's personalized mRNA cancer therapy, developed with Merck, reduced the risk of melanoma recurrence and spread in a ...

Moderna's mRNA vaccine combined with Merck's immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the ...

Moderna and Merck have been running a large Phase III trial in over a thousand high-risk patients who had already had surgery ...

Merck and Moderna say the experimental treatment extended the time before skin cancer returned in patients at high risk.

As the dust settles on a phase 3 announcement that added $45 billion to Moderna’s market cap, analysts have begun to ask a ...